Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
NCT03397186 is a phase 2 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it was withdrawn. It studies Trabectedin in Metastatic Soft Tissue Sarcoma, Myxoid Liposarcoma and 4 more conditions. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 19 Jun 2018 and a primary completion date of 1 Jan 2021. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03397186 |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Fred Hutchinson Cancer Center |
| Enrollment | 0 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Metastatic Soft Tissue Sarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7 and Unresectable Soft Tissue Sarcoma |
| Drugs | Trabectedin |
| Start | 19 Jun 2018 |
| Primary completion | 1 Jan 2021 |
| Study completion | 1 May 2021 |
| Last update posted | 10 Sept 2019 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Seth Pollack
Fred Hutch/University of Washington Cancer Consortium
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fred Hutch/university of Washington Cancer Consortium
Seattle
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03397186
Each answer restates registry values shown on this page.
What is NCT03397186?
NCT03397186 is a phase 2 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Trabectedin in Metastatic Soft Tissue Sarcoma, Myxoid Liposarcoma and 4 more conditions.
Who leads NCT03397186?
The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.
Where does NCT03397186 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03397186 study?
The registered drug and biological interventions are Trabectedin.
When did NCT03397186 end?
The registry lists a primary completion date of 1 Jan 2021 and a study completion date of 1 May 2021. The sponsor last updated the record on 10 Sept 2019.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.